Hirudin in renal insufficiency
Research article published in Seminars in thrombosis and hemostasis (2002)
Abstract
Recombinant hirudins (r-hirudins) are potent direct thrombin inhibitors increasingly used for alternative anticoagulation, especially in heparin-induced thrombocytopenia. R-hirudins are almost exclusively eliminated by the kidneys, and a close correlation between r-hirudin clearance and endogenous creatinine clearance has been observed. Accordingly, the pharmacokinetics of r-hirudin are altered in patients with renal insufficiency. A decline of renal r-hirudin clearance is associated with an increase of r-hirudin half-life and the area under the curve (AUC). Therefore, renal impairment necessitates reduction of r-hirudin dose to avoid overdose or inadequate accumulation of the thrombin inhibitor. To this end, close monitoring of r-hirudin anticoagulation is required, which at best is performed by measuring r-hirudin blood levels by ecarin clotting times (ECT) or chromogenic assays, in addition to activated partial thromboplastin time (aPTT). Recent studies showed that r-hirudin anticoagulation is feasible in acute or chronic renal failure treated with continuous or intermittent renal replacement therapy, if appropriate r-hirudin dosing and adequate monitoring are warranted. High-volume hemofiltration with r-hirudin-permeable hemodialyzers constitutes a valuable means to markedly reduce r-hirudin blood concentration and total r-hirudin body content in case of r-hirudin overdose or r-hirudin-associated bleeding. In the future, the hepatically eliminated direct thrombin inhibitor argatroban may facilitate alternative anticoagulation in patients with renal insufficiency.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Recombinant hirudins (r-hirudins) are potent direct thrombin inhibitors increasingly used for alternative anticoagulation, especially in heparin-induced thrombocytopenia.
Why This Matters for Hirudotherapy
This review examines the pharmacokinetics, dosing, and clinical monitoring of recombinant hirudins (r-hirudins)—potent direct thrombin inhibitors—in patients with renal insufficiency, documenting how reduced renal clearance prolongs half-life and increases the area under the curve, necessitating dose reduction and close monitoring. The detailed pharmacological information on hirudin elimination, accumulation risk, monitoring strategies (ecarin clotting time, chromogenic assays, aPTT), and removal during renal replacement therapy is relevant to understanding hirudin-based anticoagulation within the ASH domain. However, the article addresses pharmaceutical recombinant hirudins for systemic clinical anticoagulation in conditions such as heparin-induced thrombocytopenia; it does not involve leeches, leech therapy, or leech-derived materials, and the abstract provides no original quantitative outcome data.
Citation
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026